These in vivo data further support the roles of gefitinib-induced LPIN1 expression and NF-κB activation in cell survival (Figure 6D) and the importance of LPIN1 as a potential target to prevent gefitinib resistance in EGFR-mutant NSCLC. Here, NFKB1 is linked to non-small cell lung carcinoma.